A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
Status:
Recruiting
Trial end date:
2027-01-15
Target enrollment:
Participant gender:
Summary
This phase III trial compares the effect of vinorelbine with vincristine, dactinomycin, and
cyclophosphamide (VAC) followed by vinorelbine and cyclophosphamide versus VAC followed by
vinorelbine and cyclophosphamide for the treatment of high risk rhabdomyosarcoma.
Chemotherapy drugs, such as vinorelbine, vincristine, dactinomycin, and cyclophosphamide,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Giving vinorelbine and VAC
may kill more tumor cells. Adding maintenance therapy (vinorelbine and cyclophosphamide)
after VAC therapy, with or without vinorelbine, may help get rid of the cancer and/or lower
the chance that the cancer comes back.